Key result
AAV-mediated GLP-1 9-37 overexpression reduces septal thickness and cardiac fibrosis in pressure overload.
Why the study?
Although both GLP-1(7-37) and its degradation product GLP-1(9-37) exhibit cardioprotective effects, the underlying mechanisms are unclear and the role of GLP-1(9-37) remains poorly understood.
Does AAV-mediated overexpression of GLP-1(9-37) improve left ventricular function and mitigate adverse cardiac remodelling in a murine model of cardiac pressure overload?
Does AAV-mediated overexpression of GLP-1(9-37) improve left ventricular function and mitigate adverse cardiac remodelling in a murine model of cardiac pressure overload?
In a murine model of cardiac pressure overload, AAV-mediated overexpression of GLP-1(9-37) attenuates structural hypertrophy and cardiac fibrosis while activating AMPK/PGC1α mitochondrial biogenesis pathways without affecting glucose metabolism.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for GLP-1(9-37) in pressure-overload HF; prospective human studies needed before clinical adoption.
AIM: Glucagon-like peptide-1 (GLP-1) is an incretin hormone that is released in response to nutrient intake and inflammation. Its active form, GLP-1(7-37), binds to the GLP-1 receptor (GLP-1R), but GLP-1 is rapidly degraded by dipeptidyl peptidase-4 (DPP-4) into GLP-1(9-37), which does not bind to the classical GLP-1R. Both peptides exhibit cardioprotective effects, although the underlying mechanisms are unclear and the role of GLP-1(9-37) remains poorly understood. METHODS AND RESULTS: In this study, we investigated cardiac and metabolic effects of GLP-1(9-37) in a mouse model of cardiac pressure overload. LacZ and GLP-1(9-37) were overexpressed using an AAV vector system. While GLP-1(9-37) does not affect glucose metabolism, it mechanistically activates key metabolic regulators, as evidenced by increased AMPK and PGC1α signalling. This shift suggests an improvement in cellular energy balance and mitochondrial function under hypertrophic stress conditions. GLP-1(9-37) was also found to mitigate adverse cardiac remodelling. Treatment is associated with reduced septal thickness and decreased cardiac fibrosis, indicating attenuation of structural hypertrophy. CONCLUSIONS: In summary, our data suggest a protective role of GLP-1(9-37) in pressure-overload-induced cardiac remodelling, which is associated with AMPK/PGC1α-signalling.
No takes yet. Share an insight, caveat, or question.
Möllmann et al. (2026) studied Cardiac pressure overload (murine model). GLP-1(9-37) overexpression via AAV vector vs. LacZ overexpression via AAV vector was evaluated on Left ventricular function, adverse cardiac remodelling (septal thickness, cardiac fibrosis), and AMPK/PGC1α signalling. AAV-mediated GLP-1(9-37) overexpression in mice with cardiac pressure overload reduced septal thickness and cardiac fibrosis while increasing AMPK/PGC1α signalling compared with LacZ.
Synapse has enriched 10 related papers. Consider them for comparative context: